Change in Plasma Biomarkers of Alzheimer’s Disease From Midlife to Late-Life and Associations With Cognitive Change

Abstract

Plasma biomarkers of Alzheimer’s disease (AD) pathology offer a non-invasive method to assess brain changes linked to dementia and cognitive decline. However, the associations with specific cognitive domains and subsequent cognitive change in participants with or without cognitive impairment is unclear.